Skip to main content
Top
Published in: Medical Oncology 4/2011

01-12-2011 | Original Paper

MDM2 309 T/G polymorphism is associated with colorectal cancer risk especially in Asians: a meta-analysis

Authors: Fang Fang, Xiao-Jia Yu, Lu Yu, Lei Yao

Published in: Medical Oncology | Issue 4/2011

Login to get access

Abstract

The murine double minute 2 (MDM2) gene encodes an important regulator which mainly functions as an E3 ligase. The role of the MDM2 protein in the P53 pathway has been especially well-studied. In this study, our aim was to explore the relationship between MDM2 gene 309 T/G polymorphism and colorectal cancer risk. Performing both the overall meta-analysis and the subgroup meta-analysis based on ethnicity and source of controls with a total of 7 eligible studies (2,543 cases and 2,115 controls in all), we detected a significant colorectal cancer risk variation for TG versus GG (OR = 0.73, 95% CI = 0.62–0.86) in the overall analysis and another significant colorectal cancer risk variation for TG versus GG (OR = 0.70, 95% CI = 0.59–0.83) in the population-based controls’ subgroup as well. Moreover, in the subgroup analysis based on ethnicity, significant associations were observed for all genetic models in Asians (OR = 0.51, 95% CI = 0.41–0.64 for TT versus GG; OR = 0.64, 95% CI = 0.53–0.78 for TG versus GG; OR = 0.59, 95% CI = 0.49–0.71 for dominant model; OR = 0.69, 95% CI = 0.57–0.82 for recessive model), while in Caucasians there was no obvious association. In summary, according to the results of our meta-analysis, the MDM2 309 G allele probably acts as a colorectal cancer risk factor, especially in Asians.
Literature
1.
go back to reference Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 1992;69:1237–45.PubMedCrossRef Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 1992;69:1237–45.PubMedCrossRef
2.
go back to reference Michael D, Oren M. The p53-Mdm2 module and the ubiquitin system. Semin Cancer Biol. 2003;13:49–58.PubMedCrossRef Michael D, Oren M. The p53-Mdm2 module and the ubiquitin system. Semin Cancer Biol. 2003;13:49–58.PubMedCrossRef
3.
go back to reference Bond GL, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004;119:591–602.PubMedCrossRef Bond GL, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004;119:591–602.PubMedCrossRef
4.
go back to reference Nunobiki O, et al. Polymorphisms of p53 codon 72 and MDM2 promoter 309 and the risk of endometrial cancer. Hum Cell. 2009;22:101–6.PubMedCrossRef Nunobiki O, et al. Polymorphisms of p53 codon 72 and MDM2 promoter 309 and the risk of endometrial cancer. Hum Cell. 2009;22:101–6.PubMedCrossRef
5.
go back to reference Economopoulos KP, Sergentanis TN. Differential effects of MDM2 SNP309 polymorphism on breast cancer risk along with race: a meta-analysis. Breast Cancer Res Treat. 2010;120:211–6.PubMedCrossRef Economopoulos KP, Sergentanis TN. Differential effects of MDM2 SNP309 polymorphism on breast cancer risk along with race: a meta-analysis. Breast Cancer Res Treat. 2010;120:211–6.PubMedCrossRef
6.
go back to reference Kang S, et al. Association of p73 and MDM2 polymorphisms with the risk of epithelial ovarian cancer in Chinese women. Int J Gynecol Cancer. 2009;19:572–7.PubMedCrossRef Kang S, et al. Association of p73 and MDM2 polymorphisms with the risk of epithelial ovarian cancer in Chinese women. Int J Gynecol Cancer. 2009;19:572–7.PubMedCrossRef
7.
go back to reference Ueda M, et al. Murine double-minute 2 homolog single nucleotide polymorphism 309 and the risk of gynecologic cancer. Hum Cell. 2009;22:49–54.PubMedCrossRef Ueda M, et al. Murine double-minute 2 homolog single nucleotide polymorphism 309 and the risk of gynecologic cancer. Hum Cell. 2009;22:49–54.PubMedCrossRef
8.
go back to reference Markowitz SD, Bertagnolli MM. Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med. 2009;361:2449–60.PubMedCrossRef Markowitz SD, Bertagnolli MM. Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med. 2009;361:2449–60.PubMedCrossRef
9.
go back to reference Wilkening S, Bermejo JL, Hemminki K. MDM2 SNP309 and cancer risk: a combined analysis. Carcinogenesis. 2007;28:2262–7.PubMedCrossRef Wilkening S, Bermejo JL, Hemminki K. MDM2 SNP309 and cancer risk: a combined analysis. Carcinogenesis. 2007;28:2262–7.PubMedCrossRef
10.
go back to reference Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med. 1997;127:820–6.PubMed Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med. 1997;127:820–6.PubMed
11.
go back to reference Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMed Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMed
12.
13.
go back to reference Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.PubMedCrossRef Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.PubMedCrossRef
14.
go back to reference Alhopuro P, et al. The MDM2 promoter polymorphism SNP309T → G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck. J Med Genet. 2005;42:694–8.PubMedCrossRef Alhopuro P, et al. The MDM2 promoter polymorphism SNP309T → G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck. J Med Genet. 2005;42:694–8.PubMedCrossRef
15.
go back to reference Sotamaa K, et al. p53 codon 72 and MDM2 SNP309 polymorphisms and age of colorectal cancer onset in Lynch syndrome. Clin Cancer Res. 2005;11:6840–4.PubMedCrossRef Sotamaa K, et al. p53 codon 72 and MDM2 SNP309 polymorphisms and age of colorectal cancer onset in Lynch syndrome. Clin Cancer Res. 2005;11:6840–4.PubMedCrossRef
16.
go back to reference Menin C, et al. Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status. J Natl Cancer Inst. 2006;98:285–8.PubMedCrossRef Menin C, et al. Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status. J Natl Cancer Inst. 2006;98:285–8.PubMedCrossRef
17.
go back to reference Alazzouzi H, et al. Tumour selection advantage of non-dominant negative P53 mutations in homozygotic MDM2-SNP309 colorectal cancer cells. J Med Genet. 2007;44:75–80.PubMedCrossRef Alazzouzi H, et al. Tumour selection advantage of non-dominant negative P53 mutations in homozygotic MDM2-SNP309 colorectal cancer cells. J Med Genet. 2007;44:75–80.PubMedCrossRef
18.
go back to reference Talseth BA, et al. MDM2 SNP309 T > G alone or in combination with the TP53 R72P polymorphism does not appear to influence disease expression and age of diagnosis of colorectal cancer in HNPCC patients. Int J Cancer. 2007;120:563–5.PubMedCrossRef Talseth BA, et al. MDM2 SNP309 T > G alone or in combination with the TP53 R72P polymorphism does not appear to influence disease expression and age of diagnosis of colorectal cancer in HNPCC patients. Int J Cancer. 2007;120:563–5.PubMedCrossRef
19.
go back to reference Liu JN, et al. Genetic polymorphism in MDM2 is associated with susceptibility to colorectal cancer in a Chinese population. Zhonghua Zhong Liu Za Zhi. 2008;30:335–8.PubMed Liu JN, et al. Genetic polymorphism in MDM2 is associated with susceptibility to colorectal cancer in a Chinese population. Zhonghua Zhong Liu Za Zhi. 2008;30:335–8.PubMed
20.
go back to reference Chen YL, Chang YS, Chang JG, Wu SM. Genotyping of single nucleotide polymorphism in MDM2 genes by universal fluorescence primer PCR and capillary electrophoresis. Anal Bioanal Chem. 2009;394:1291–7.PubMedCrossRef Chen YL, Chang YS, Chang JG, Wu SM. Genotyping of single nucleotide polymorphism in MDM2 genes by universal fluorescence primer PCR and capillary electrophoresis. Anal Bioanal Chem. 2009;394:1291–7.PubMedCrossRef
Metadata
Title
MDM2 309 T/G polymorphism is associated with colorectal cancer risk especially in Asians: a meta-analysis
Authors
Fang Fang
Xiao-Jia Yu
Lu Yu
Lei Yao
Publication date
01-12-2011
Publisher
Springer US
Published in
Medical Oncology / Issue 4/2011
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-010-9577-1

Other articles of this Issue 4/2011

Medical Oncology 4/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.